Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2004; 44:750-758, doi:10.1016/j.jacc.2004.05.044
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Windecker, S.
Right arrow Articles by Meier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Windecker, S.
Right arrow Articles by Meier, B.

Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke

Stephan Windecker, MD*,*, Andreas Wahl, MD*, Krassen Nedeltchev, MD{dagger}, Marcel Arnold, MD{dagger}, Markus Schwerzmann, MD*, Christian Seiler, MD, FACC*, Heinrich P. Mattle, MD{dagger} and Bernhard Meier, MD, FACC*,*

* Cardiology
{dagger} Neurology, University Hospital, Bern,Switzerland



View larger version (18K):

[in a new window]
 
Figure 1 Probability of death, recurrent stroke, or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line).

 


View larger version (18K):

[in a new window]
 
Figure 2 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line).

 


View larger version (19K):

[in a new window]
 
Figure 3 Risk ratios according to treatment assignment in subgroups. PFO = patent foramen ovale; ASA = atrial septal aneurysm.

 


View larger version (20K):

[in a new window]
 
Figure 4 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line) in the subgroup of patients with complete PFO occlusion.

 


View larger version (19K):

[in a new window]
 
Figure 5 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line) in the subgroup of patients with more than one cerebrovascular event at baseline.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement